Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 5
2014 5
2015 2
2016 2
2017 5
2018 7
2019 2
2020 1
2021 3
2022 3
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 0000-0002-3977-4017
Page 1
Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.
O'Neill AF, Zeme EL, Abou-Alfa GK, Baretti M, Bondoc AJ, Church A, Ferrone CR, Fitzgerald M, Geller JI, Gill AE, Harris WP, Kim HB, Lee SS, Liu KX, Ortiz MV, Rangaswami A, Riehle KJ, Rosenberg AR, Torbenson MS, Yarchoan M, Gordan JD. O'Neill AF, et al. Among authors: harris wp. Hepatology. 2026 Mar 18. doi: 10.1097/HEP.0000000000001700. Online ahead of print. Hepatology. 2026. PMID: 41849750 No abstract available.
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.
Chiorean EG, Damle SR, Zhen DB, Whittle M, George B, Hochster H, Coveler AL, Hendifar A, Dragovich T, Safyan RA, King GT, Harris WP, Dion B, Stoll D'Astice A, Lee A, Thorsen S, Kugel S, Rosenthal A, Hingorani S. Chiorean EG, et al. Among authors: harris wp. Cancers (Basel). 2026 Feb 3;18(3):507. doi: 10.3390/cancers18030507. Cancers (Basel). 2026. PMID: 41681979 Free PMC article.
This multicenter phase II study of PEGPH20 plus pembrolizumab evaluated the efficacy, safety and immune and stromal biomarkers in patients with HA-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA). Patients and Methods: Patients were treated with PEGPH20 3 …
This multicenter phase II study of PEGPH20 plus pembrolizumab evaluated the efficacy, safety and immune and stromal biomarkers in patients w …
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
El-Khoueiry AB, Kim RD, Harris WP, Sung MW, Waldschmidt D, Cabrera R, Garosi VL, Ploeger BA, Zebger-Gong H, Brennan BJ, Wang YA, Mueller U, Weispfenning A, Seidel H, Coppieters S, Ishida TC, Galle PR. El-Khoueiry AB, et al. Among authors: harris wp. Hepatology. 2025 Nov 10;83(6):1433-45. doi: 10.1097/HEP.0000000000001585. Online ahead of print. Hepatology. 2025. PMID: 41213032 Free PMC article.
Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.
King GG, Baker KK, Coveler AL, Harris WP, Cohen SA, Shankaran V, Zhen DB, Safyan RA, Lee HH, Alidina A, Hensel J, Hibbert R, Durm GA, LaFary YC, Younger A, Kugel S, Collisson E, Konnick EQ, Redman MW, Schneider BP, Pritchard CC, Shahda S, Chiorean EG. King GG, et al. Among authors: harris wp. Cancers (Basel). 2025 May 30;17(11):1830. doi: 10.3390/cancers17111830. Cancers (Basel). 2025. PMID: 40507311 Free PMC article.
This phase I trial evaluated the safety and preliminary efficacy of afatinib plus capecitabine in refractory pancreatic ductal adenocarcinoma (PDA), biliary tract cancers (BTC), and other solid tumors. ...
This phase I trial evaluated the safety and preliminary efficacy of afatinib plus capecitabine in refractory pancreatic ductal adenoc …
Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.
Li M, Hannan LM, Goyal L, Bocobo AG, Parks AL, Bauer K, Baiev I, Dinicola C, Gordan JD, Venook AP, Harris WP, Bracci P, Kelley RK. Li M, et al. Among authors: harris wp. Ther Adv Med Oncol. 2024 Nov 19;16:17588359241297085. doi: 10.1177/17588359241297085. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39563717 Free PMC article.
BACKGROUND: Early changes in alpha-fetoprotein (AFP) are a promising surrogate endpoint for systemic treatment outcomes in hepatocellular carcinoma (HCC). OBJECTIVES: We sought to investigate the utility of AFP response across first-line sorafenib (1L SOR) and later-line c …
BACKGROUND: Early changes in alpha-fetoprotein (AFP) are a promising surrogate endpoint for systemic treatment outcomes in hepatocellular …
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, Sanoff HK, Johnson MS, O'Neil B, McRee AJ, Somasundaram A. Yu S, et al. Among authors: harris wp. Oncologist. 2024 Mar 4;29(3):270-e413. doi: 10.1093/oncolo/oyad331. Oncologist. 2024. PMID: 38325328 Free PMC article. Clinical Trial.
BACKGROUND: Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT030995 …
BACKGROUND: Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the …
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC, Hannan LM, Zhen DB, Coveler AL, King G, Cohen SA, Harris WP, Shankaran V, Wong KM, Green S, Ng N, Pillarisetty VG, Sham JG, Park JO, Reddi D, Konnick EQ, Pritchard CC, Baker K, Redman M, Chiorean EG. Diehl AC, et al. Among authors: harris wp. Oncologist. 2022 Dec 9;27(12):1025-1033. doi: 10.1093/oncolo/oyac179. Oncologist. 2022. PMID: 36124727 Free PMC article.
BACKGROUND: KRAS variant alleles may have differential biological properties which impact prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). MATERIALS AND METHODS: We retrospectively identified patients with advanced PDA who received first-line t …
BACKGROUND: KRAS variant alleles may have differential biological properties which impact prognosis and therapeutic options in pancreatic …
The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM, King GG, Harris WP. Wong KM, et al. Among authors: harris wp. Curr Oncol Rep. 2022 Jul;24(7):917-927. doi: 10.1007/s11912-022-01247-7. Epub 2022 Mar 26. Curr Oncol Rep. 2022. PMID: 35347594 Review.
The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly evolved. Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy and more favorable toxicity profiles compared to multikinase inhibitors. ...
The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly evolved. Immune checkpoint inhibitors (ICIs) have …
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Zhu AX, et al. Among authors: harris wp. JAMA Oncol. 2021 Nov 1;7(11):1669-1677. doi: 10.1001/jamaoncol.2021.3836. JAMA Oncol. 2021. PMID: 34554208 Free PMC article. Clinical Trial.
IMPORTANCE: Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placeb …
IMPORTANCE: Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarc …
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. Among authors: harris w. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Free PMC article. Clinical Trial.
PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular …
PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab ( …
37 results